Table 1.
Subjects clinical and laboratory information.
| Nano-curcumin group (n = 20) | Placebo group (n = 20) | P value | Healthy Control (n = 40) | |
|---|---|---|---|---|
| Age, Years | 19–69 (53.3 ± 8.4) | 21–67 (51.4 ± 7.9) | 22–65 (49.8 ± 8.3) | |
| Sex | ||||
| Men | 15 (77%) | (80%)16 | NS | 30 (75%) |
| Women | 5 (22%) | (20%)4 | 10 (25%) | |
| Current smoking | 4 (20%) | (15%)3 | NS | 9 (18%) |
| Diabetes | 2 (10%) | (5%)1 | NS | 0 |
| Hypertension | 1 (5%) | (5%)1 | NS | 0 |
| Cardiovascular disease | 2 (10%) | (15%)3 | NS | 0 |
| Chronic kidney disease | 0 | (5%)1 | _ | |
| Fever | ||||
| <37.3 °C | 1 (5%) | 0 | NS | 0 |
| 37.3–38.0 °C | 9 (45%) | 8 (40%) | ||
| 38.1–39.0 °C | 7 (37%) | 7 (35%) | ||
| >39.0 °C | 4 (20%) | 5 (25%) | ||
| Cough | 12 (60%) | 11 (55%) | NS | 0 |
| Headache | 1 (5%) | 2 (10%) | NS | 0 |
| Dyspnea | 5 (25%) | 4 (20%) | NS | 0 |
| White blood cell count, × 109/L | ||||
| <4 | 5 (25%) | (25%)5 | NS | 0 |
| 4–10 | 9 (45%) | (40%)8 | ||
| >10 | 6 (30%) | (35%)7 | ||
| Lymphocyte count, × 109/L | ||||
| <1·0 | 13 (65%) | 11 (55%) | NS | 0 |
| ≥1·0 | 7 (35%) | 9 (45%) | ||
| Platelet count, × 109/L | ||||
| <100 | 11 (55%) | 11 (55%) | NS | 0 |
| ≥100 | 9 (45%) | 8 (40%) | ||
| Creatinine, μmol/L | ||||
| ≤133 | 18 (90%) | 17 (85%) | NS | 0 |
| >133 | 2 (10%) | 3 (15%) | ||
| Lactate dehydrogenase, U/L | ||||
| ≤245 | 13 (65%) | 13 (65%) | NS | 0 |
| >245 | 7 (35%) | 7 (35%) | ||
| Bilateral involvement of chest radiographs | 19 (95%) | 19 (95%) | NS | 0 |